107 related articles for article (PubMed ID: 9232256)
21. Combination of tacrolimus, methotrexate, and methylprednisolone prevents acute but not chronic graft-versus-host disease in unrelated bone marrow transplantation.
Ogawa H; Soma T; Hosen N; Tatekawa T; Tsuboi A; Oji Y; Tamaki H; Kawakami M; Ikegame K; Murakami M; Fujioka T; Kim EH; Oka Y; Sugiyama H
Transplantation; 2002 Jul; 74(2):236-43. PubMed ID: 12151737
[TBL] [Abstract][Full Text] [Related]
22. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation.
Przepiorka D; Khouri I; Ippoliti C; Ueno NT; Mehra R; Körbling M; Giralt S; Gajewski J; Fischer H; Donato M; Cleary K; Claxton D; Chan KW; Braunschweig I; van Besien K; Andersson BS; Anderlini P; Champlin R
Bone Marrow Transplant; 1999 Oct; 24(7):763-8. PubMed ID: 10516680
[TBL] [Abstract][Full Text] [Related]
23. Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities.
Furlong T; Storb R; Anasetti C; Appelbaum FR; Deeg HJ; Doney K; Martin P; Sullivan K; Witherspoon R; Nash RA
Bone Marrow Transplant; 2000 Nov; 26(9):985-91. PubMed ID: 11100278
[TBL] [Abstract][Full Text] [Related]
24. Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan.
Koga Y; Nagatoshi Y; Kawano Y; Okamura J
Bone Marrow Transplant; 2003 Jul; 32(2):171-6. PubMed ID: 12838282
[TBL] [Abstract][Full Text] [Related]
25. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors.
Nash RA; Antin JH; Karanes C; Fay JW; Avalos BR; Yeager AM; Przepiorka D; Davies S; Petersen FB; Bartels P; Buell D; Fitzsimmons W; Anasetti C; Storb R; Ratanatharathorn V
Blood; 2000 Sep; 96(6):2062-8. PubMed ID: 10979948
[TBL] [Abstract][Full Text] [Related]
26. Short-term methotrexate could reduce early immune reactions and improve outcomes in umbilical cord blood transplantation for adults.
Narimatsu H; Terakura S; Matsuo K; Oba T; Uchida T; Iida H; Hamaguchi M; Watanabe M; Kohno A; Murata M; Sawa M; Miyamura K; Morishita Y
Bone Marrow Transplant; 2007 Jan; 39(1):31-9. PubMed ID: 17115066
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of transient treatment with FK506 in the early phase on cyclophosphamide-induced bone marrow chimerism and transplant tolerance across MHC barriers.
Okayama J; Ko S; Kanehiro H; Kanokogi H; Nakajima Y
J Surg Res; 2006 Jun; 133(2):61-8. PubMed ID: 16376943
[TBL] [Abstract][Full Text] [Related]
28. FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors.
Nash RA; Piñeiro LA; Storb R; Deeg HJ; Fitzsimmons WE; Furlong T; Hansen JA; Gooley T; Maher RM; Martin P; McSweeney PA; Sullivan KM; Anasetti C; Fay JW
Blood; 1996 Nov; 88(9):3634-41. PubMed ID: 8896434
[TBL] [Abstract][Full Text] [Related]
29. Successful treatment of steroid-resistant severe acute GVHD with 24-h continuous infusion of FK506.
Ohashi Y; Minegishi M; Fujie H; Tsuchiya S; Konno T
Bone Marrow Transplant; 1997 Mar; 19(6):625-7. PubMed ID: 9085743
[TBL] [Abstract][Full Text] [Related]
30. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation.
Bacigalupo A; Lamparelli T; Barisione G; Bruzzi P; Guidi S; Alessandrino PE; di Bartolomeo P; Oneto R; Bruno B; Sacchi N; van Lint MT; Bosi A;
Biol Blood Marrow Transplant; 2006 May; 12(5):560-5. PubMed ID: 16635791
[TBL] [Abstract][Full Text] [Related]
31. Omission of day-11 MTX, in combination with tacrolimus, is not associated with increased risk of acute graft-versus-host disease after allo-BMT.
Honda A; Kakihana K; Aoki J; Kobayashi T; Doki N; Sakamaki H; Ohashi K
Bone Marrow Transplant; 2013 Feb; 48(2):307-9. PubMed ID: 22751000
[No Abstract] [Full Text] [Related]
32. Combination of cyclosporine and methotrexate for prophylaxis of acute graft versus host disease after allogeneic bone marrow transplantation for leukaemias.
Mrsić M; Labar B; Bogdanić V; Nemet D; Pavletić Z; Plavsić F; Dobrić I; Kastelan A; Marusić M; Zupancić-Salek S
Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():95-6. PubMed ID: 2697416
[No Abstract] [Full Text] [Related]
33. [Limb allograft in rats: studies on optimal maintenance dose of FK506 and development of graft-versus-host-disease (GVHD)].
Weigao C
Fukuoka Igaku Zasshi; 1996 Sep; 87(9):197-205. PubMed ID: 8913057
[TBL] [Abstract][Full Text] [Related]
34. Cyclosporin, methotrexate and prednisolone for graft-versus-host disease prophylaxis in allogeneic peripheral blood progenitor cell transplants.
Hoyt R; Ritchie DS; Roberts AW; Macgregor L; Curtis DJ; Szer J; Grigg AP
Bone Marrow Transplant; 2008 Apr; 41(7):651-8. PubMed ID: 18176619
[TBL] [Abstract][Full Text] [Related]
35. Gastroparesis following bone marrow transplantation.
Eagle DA; Gian V; Lauwers GY; Manivel JC; Moreb JS; Mastin S; Wingard JR
Bone Marrow Transplant; 2001 Jul; 28(1):59-62. PubMed ID: 11498745
[TBL] [Abstract][Full Text] [Related]
36. Practical considerations in the use of tacrolimus for allogeneic marrow transplantation.
Przepiorka D; Devine S; Fay J; Uberti J; Wingard J
Bone Marrow Transplant; 1999 Nov; 24(10):1053-6. PubMed ID: 10578154
[TBL] [Abstract][Full Text] [Related]
37. Tacrolimus (FK506) in allogeneic bone marrow transplantation for severe aplastic anemia following orthotopic liver transplantation.
Trede NS; Warwick AB; Rosoff PM; Rohrer R; Bierer BE; Guinan E
Bone Marrow Transplant; 1997 Aug; 20(3):257-60. PubMed ID: 9257897
[TBL] [Abstract][Full Text] [Related]
38. Thrombotic microangiopathy following allogeneic bone marrow transplantation is associated with intensive graft-versus-host disease prophylaxis.
Paquette RL; Tran L; Landaw EM
Bone Marrow Transplant; 1998 Aug; 22(4):351-7. PubMed ID: 9722070
[TBL] [Abstract][Full Text] [Related]
39. Tacrolimus vs. cyclosporine immunosuppression: results in advanced-stage disease compared with historical controls treated exclusively with cyclosporine.
Horowitz MM; Przepiorka D; Bartels P; Buell DN; Zhang MJ; Fitzsimmons WE; Erdman J; Huang C; Hodosh E; Maher R; Wingard JR
Biol Blood Marrow Transplant; 1999; 5(3):180-6. PubMed ID: 10392964
[TBL] [Abstract][Full Text] [Related]
40. A new marrow T cell depletion method using anti-CD6 monoclonal antibody-conjugated magnetic beads and its clinical application for prevention of acute graft-vs.-host disease in allogeneic bone marrow transplantation: results of a phase I-II trial.
Sao H; Kitaori K; Kasai M; Shimokawa T; Kato C; Yamanishi H; Ueda R; Morishima Y
Int J Hematol; 1999 Jan; 69(1):27-35. PubMed ID: 10641440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
